From the pages of AllergyWatch (R)

• Authors: Stanley Fineman, Emory University; Gerald Lee, Emory University; Todd Mahr, University of Wisconsin; Bradley E. Chipps, Capital Allergy and Respiratory Disease Center
• Journal Title: Annals of Allergy, Asthma & Immunology
• Volume: Volume 126, Number 4
• Publisher: Elsevier Science Inc. | 2021-03-26, Pages 444-445
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1016/j.anai.2021.01.005
• Subjects: Health Sciences, Immunology; Health Sciences, Health Care Management; Health Sciences, Public Health; Health Sciences, Human Development
• Keywords: Science & Technology; Life Sciences & Biomedicine; Allergy; Immunology

Abstract

For this issue of “From the Pages of AllergyWatch,” I have selected 2 articles related to coronavirus disease 2019 (COVID-19) and asthma. The first review by Dr Lee from the November-December AllergyWatch postulates that the angiotensin-converting enzyme 2 (ACE2) receptors may be protective in our patients with allergic asthma and reduce the risk for hospitalization with COVID-19. The next article, reviewed by Dr Mahr from the September-October AllergyWatch, warns about stepping down controllers in pediatric patients with asthma during the pandemic. The last article, reviewed by Dr Chipps, evaluated the role of exhaled nitric oxide (eNO) as a guide to inhaled corticosteroid (ICS) stepdown decisions for our patients with asthma